Literature DB >> 19168158

Metabolic syndrome in rheumatological diseases.

Rosa Maria Rodrigues Pereira1, Jozélio Freire de Carvalho, Eloísa Bonfá.   

Abstract

Metabolic syndrome is characterized by a combination of various cardiovascular risk factors (age, gender, smoking, hypertension and dyslipidemia) that imply additional cardiovascular morbidity that is greater than the sum of the risks associated with each individual component. Herein, the authors review the rheumatological diseases in which metabolic syndrome has been studied: gout, osteoarthritis, systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome and ankylosing spondylitis. The prevalence of metabolic syndrome in these disorders varies from 14% to 62.8%. The great majority of these studies demonstrated that this frequency was higher in rheumatological diseases than in the control populations, suggesting that either the presence or the treatment of those diseases seems to influence the risk of developing metabolic syndrome.

Entities:  

Mesh:

Year:  2009        PMID: 19168158     DOI: 10.1016/j.autrev.2009.01.001

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  26 in total

1.  Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study.

Authors:  Luisa Costa; Francesco Caso; Roberta Ramonda; Antonio Del Puente; Luca Cantarini; Md Abud Darda; Paolo Caso; Mariagrazia Lorenzin; Ugo Fiocco; Leonardo Punzi; Raffaele Scarpa
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

2.  [Diabetes and rheumatism: is diabetes mellitus also an inflammatory disease?].

Authors:  S Graf; P-M Schumm-Draeger
Journal:  Z Rheumatol       Date:  2011-11       Impact factor: 1.372

3.  Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis.

Authors:  Smriti K Raychaudhuri; Sidhartha Chatterjee; Caroline Nguyen; Manpreet Kaur; Ishwarlal Jialal; Siba P Raychaudhuri
Journal:  Metab Syndr Relat Disord       Date:  2010-08       Impact factor: 1.894

4.  [Therapy of dyslipidemia in rheumatic diseases].

Authors:  S Vordenbäumen; S Schinner; M Halle; R Fischer-Betz; M Schneider
Journal:  Z Rheumatol       Date:  2010-10       Impact factor: 1.372

5.  Metabolic syndrome in Sjögren's syndrome patients: a relevant concern for clinical monitoring.

Authors:  Kristopherson Lustosa Augusto; Eloisa Bonfa; Rosa Maria Rodrigues Pereira; Cleonice Bueno; Elaine Pires Leon; Vilma Santos Trindade Viana; Sandra Gofinet Pasoto
Journal:  Clin Rheumatol       Date:  2015-09-14       Impact factor: 2.980

6.  Impact of 24-month treatment with etanercept, adalimumab, or methotrexate on metabolic syndrome components in a cohort of 210 psoriatic arthritis patients.

Authors:  Luisa Costa; Francesco Caso; Mariangela Atteno; Antonio Del Puente; Md Abud Darda; Paolo Caso; Augusta Ortolan; Ugo Fiocco; Roberta Ramonda; Leonardo Punzi; Raffaele Scarpa
Journal:  Clin Rheumatol       Date:  2014-06       Impact factor: 2.980

7.  Leptin, adiponectin and vascular stiffness parameters in women with systemic lupus erythematosus.

Authors:  Marta Vadacca; Enrico M Zardi; Domenico Margiotta; Amelia Rigon; Fabio Cacciapaglia; Luisa Arcarese; Francesca Buzzulini; Antonio Amoroso; Antonella Afeltra
Journal:  Intern Emerg Med       Date:  2011-11-30       Impact factor: 3.397

8.  Tryptophan depletion under conditions that imitate insulin resistance enhances fatty acid oxidation and induces endothelial dysfunction through reactive oxygen species-dependent and independent pathways.

Authors:  Theodoros Eleftheriadis; Georgios Pissas; Maria Sounidaki; Georgia Antoniadi; Christos Rountas; Vassilios Liakopoulos; Loannis Stefanidis
Journal:  Mol Cell Biochem       Date:  2017-02-04       Impact factor: 3.396

9.  Myocardial ischemia in Wegener's granulomatosis: coronary atherosclerosis versus vasculitis.

Authors:  Giuseppe Cocco; Armen Yuri Gasparyan
Journal:  Open Cardiovasc Med J       Date:  2010-02-23

Review 10.  Type 2 Diabetes Mellitus, Insulin Resistance, and Vitamin D.

Authors:  Alan Sacerdote; Paulomi Dave; Vladimir Lokshin; Gül Bahtiyar
Journal:  Curr Diab Rep       Date:  2019-09-10       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.